Medtronic PLC $MDT Holdings Lifted by King Luther Capital Management Corp

King Luther Capital Management Corp increased its holdings in shares of Medtronic PLC (NYSE:MDT) by 93.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 61,870 shares of the medical technology company’s stock after buying an additional 29,968 shares during the quarter. King Luther Capital Management Corp’s holdings in Medtronic were worth $5,943,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in the stock. ICW Investment Advisors LLC boosted its holdings in shares of Medtronic by 2.1% during the fourth quarter. ICW Investment Advisors LLC now owns 16,869 shares of the medical technology company’s stock worth $1,620,000 after purchasing an additional 342 shares during the period. TrustBank acquired a new stake in shares of Medtronic during the fourth quarter worth approximately $105,000. Roundview Capital LLC boosted its holdings in shares of Medtronic by 27.5% during the fourth quarter. Roundview Capital LLC now owns 2,830 shares of the medical technology company’s stock worth $272,000 after purchasing an additional 610 shares during the period. Flputnam Investment Management Co. boosted its holdings in shares of Medtronic by 287.4% during the fourth quarter. Flputnam Investment Management Co. now owns 20,537 shares of the medical technology company’s stock worth $1,973,000 after purchasing an additional 15,236 shares during the period. Finally, Valtinson Bruner Financial Planning LLC boosted its holdings in shares of Medtronic by 1.1% during the fourth quarter. Valtinson Bruner Financial Planning LLC now owns 18,003 shares of the medical technology company’s stock worth $1,729,000 after purchasing an additional 195 shares during the period. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on MDT. Barclays increased their price objective on Medtronic from $118.00 to $120.00 and gave the stock an “overweight” rating in a report on Wednesday, April 1st. Robert W. Baird increased their price objective on Medtronic from $92.00 to $93.00 and gave the stock a “neutral” rating in a report on Wednesday, April 15th. Citigroup cut their price objective on Medtronic from $117.00 to $110.00 and set a “buy” rating for the company in a report on Tuesday, April 7th. JPMorgan Chase & Co. cut their price objective on Medtronic from $105.00 to $100.00 and set a “neutral” rating for the company in a report on Wednesday, February 18th. Finally, Evercore set a $106.00 price objective on Medtronic and gave the stock an “outperform” rating in a report on Thursday, April 9th. Fifteen investment analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $106.45.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic’s Evolut TAVR platform was highlighted for superior clinical outcomes, which could support the company’s competitive position in a market expected to grow from $7.0 billion in 2025 to $13.8 billion by 2035. Medtronic’s Evolut displays superior clinical outcomes
• Positive Sentiment: Some commentary suggests Medtronic may be trading closer to fair value after its recent pullback, with M&A activity, FDA clearances, and product strength providing longer-term upside potential. Medtronic’s Fair Value Falls Between Caution And Optimism
• Neutral Sentiment: Analysts continue to frame Medtronic as a mixed story into earnings, with some seeing the stock as fairly valued after its decline and others watching whether acquisitions and new product approvals can offset slower growth. Can Medtronic (MDT) Close the Growth Gap With Its Bigger MedTech Rivals?
• Neutral Sentiment: Medtronic is scheduled to report earnings on June 3, and coverage ahead of the release has focused on expectations for a earnings decline, which is keeping sentiment cautious. Analysts Estimate Medtronic (MDT) to Report a Decline in Earnings: What to Look Out for
• Negative Sentiment: Investor sentiment remains pressured ahead of earnings, with the stock recently down over short time frames and a voluntary Class II software recall adding another near-term headwind. Medtronic (MDT) Valuation Check As Earnings Approach And M&A FDA Moves And Recall Shape Sentiment
• Negative Sentiment: Recent trading showed Medtronic slipping despite a broader market advance, reinforcing the view that investors are rotating out of the name until the earnings update provides more clarity. Medtronic (MDT) Stock Drops Despite Market Gains: Important Facts to Note

Medtronic Stock Performance

Shares of MDT opened at $75.56 on Friday. The company has a market capitalization of $97.01 billion, a PE ratio of 21.05, a price-to-earnings-growth ratio of 1.81 and a beta of 0.62. Medtronic PLC has a one year low of $74.40 and a one year high of $106.33. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. The company’s fifty day moving average price is $82.63 and its 200 day moving average price is $92.78.

Medtronic Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, April 17th. Shareholders of record on Friday, March 27th were issued a $0.71 dividend. The ex-dividend date of this dividend was Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a yield of 3.8%. Medtronic’s dividend payout ratio (DPR) is 79.11%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).